UA95954C2 - Продолжительное 24-часовое введение в кишечник леводопа/карбидопа - Google Patents
Продолжительное 24-часовое введение в кишечник леводопа/карбидопаInfo
- Publication number
- UA95954C2 UA95954C2 UAA200814421A UAA200814421A UA95954C2 UA 95954 C2 UA95954 C2 UA 95954C2 UA A200814421 A UAA200814421 A UA A200814421A UA A200814421 A UAA200814421 A UA A200814421A UA 95954 C2 UA95954 C2 UA 95954C2
- Authority
- UA
- Ukraine
- Prior art keywords
- levodopa
- carbidopa
- long term
- intestinal administration
- hour
- Prior art date
Links
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области медицины и касается применения леводопа и необязательно карбидопа для приготовления лекарственного средства, предназначенного для лечения болезни Паркинсона, для беспрерывного введения в кишечник на протяжении периода времени, которое составляет 24 ч. в день, где композицию, которая содержит леводоп и необязательно карбидоп в форме частиц, суспендируют в водном носителе, где частицы имеют максимальный размер, который не превышает 80 мкм, и где носитель имеет вязкость, которая составляет по меньшей мере 300 мПа при умеренной скорости сдвига, где суточная доза леводопа составляет от 0,5 до 5000 мг и где введение осуществляют в виде продолжительного лечения на протяжении более 1 дня.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80988906P | 2006-05-31 | 2006-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA95954C2 true UA95954C2 (ru) | 2011-09-26 |
Family
ID=38434843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200814421A UA95954C2 (ru) | 2006-05-31 | 2007-05-31 | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080051459A1 (ru) |
| EP (1) | EP2063865A1 (ru) |
| JP (1) | JP2009543761A (ru) |
| KR (1) | KR20090057349A (ru) |
| CN (1) | CN101636145B (ru) |
| AU (1) | AU2007267135B2 (ru) |
| BR (1) | BRPI0711882A2 (ru) |
| CA (1) | CA2653683A1 (ru) |
| HK (1) | HK1137931A1 (ru) |
| IL (1) | IL195599A0 (ru) |
| MX (1) | MX2008015339A (ru) |
| NO (1) | NO20085418L (ru) |
| RU (1) | RU2484815C2 (ru) |
| UA (1) | UA95954C2 (ru) |
| WO (1) | WO2007138086A1 (ru) |
| ZA (1) | ZA200810834B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2252284B1 (en) | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability |
| DK2432454T3 (en) * | 2009-05-19 | 2017-06-19 | Neuroderm Ltd | COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS |
| PL3326615T3 (pl) * | 2010-11-15 | 2020-07-27 | Neuroderm Ltd | Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| EP2653179B1 (en) | 2012-04-17 | 2019-07-10 | Micrel Medical Devices S.A. | System for calculating and administering a drug to a patient with Parkinson's disease |
| HUE042425T2 (hu) | 2012-06-05 | 2019-06-28 | Neuroderm Ltd | Apomorfint és szerves savakat tartalmazó készítmények és alkalmazásaik |
| EP4299128A3 (en) | 2014-03-13 | 2024-04-17 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PL3782617T3 (pl) | 2014-09-04 | 2024-06-24 | Lobsor Pharmaceuticals Aktiebolag | Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon |
| PT3209302T (pt) | 2014-10-21 | 2019-07-19 | Abbvie Inc | Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| EP3291872A4 (en) | 2015-05-06 | 2019-02-13 | SynAgile Corporation | PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| US20180021280A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and Carbidopa Intestinal Gel and Methods of Use |
| EP3500246B1 (en) | 2016-08-18 | 2021-08-04 | Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi | Antiparkinson tablet formulation with improved dissolution profile |
| WO2019166322A1 (en) | 2018-03-02 | 2019-09-06 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa |
| KR20200136008A (ko) | 2018-03-23 | 2020-12-04 | 롭서 파마슈티컬스 악티에볼라그 | 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여 |
| WO2019191353A1 (en) * | 2018-03-29 | 2019-10-03 | Riverside Pharmaceuticals Corporation | Levodopa fractionated dose composition and use |
| WO2020230089A1 (en) | 2019-05-14 | 2020-11-19 | Clexio Biosciences Ltd. | Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| CN118765198A (zh) * | 2022-01-03 | 2024-10-11 | 纽罗德姆有限公司 | 用于治疗帕金森病的方法和组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6166081A (en) * | 1997-10-09 | 2000-12-26 | Kushnir; Moshe | Methods and apparatus for treatment of Parkinson's disease |
| HUP0301465A3 (en) * | 2000-06-23 | 2006-07-28 | Teva Pharma | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| FR2829027A1 (fr) * | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| ITMI20030827A1 (it) * | 2003-04-18 | 2004-10-19 | Unihart Corp | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. |
| NZ546662A (en) * | 2003-10-20 | 2009-03-31 | Teva Pharma | Composition and dosage form for sustained effect of levodopa |
| ZA200610042B (en) * | 2004-06-04 | 2008-06-25 | Xenoport Inc | Levodopa prodrugs, and compositions and uses thereof |
| US20080020041A1 (en) * | 2004-10-19 | 2008-01-24 | Ayres James W | Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid |
| CA2613631A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| WO2007056570A2 (en) * | 2005-11-07 | 2007-05-18 | Teva Pharmaceutical Industries Ltd. | Levodopa compositions |
-
2007
- 2007-05-31 CA CA002653683A patent/CA2653683A1/en not_active Withdrawn
- 2007-05-31 CN CN200780019726.8A patent/CN101636145B/zh active Active
- 2007-05-31 UA UAA200814421A patent/UA95954C2/ru unknown
- 2007-05-31 US US11/756,297 patent/US20080051459A1/en not_active Abandoned
- 2007-05-31 KR KR1020087031660A patent/KR20090057349A/ko not_active Application Discontinuation
- 2007-05-31 JP JP2009512591A patent/JP2009543761A/ja not_active Withdrawn
- 2007-05-31 WO PCT/EP2007/055275 patent/WO2007138086A1/en active Application Filing
- 2007-05-31 ZA ZA200810834A patent/ZA200810834B/xx unknown
- 2007-05-31 MX MX2008015339A patent/MX2008015339A/es active IP Right Grant
- 2007-05-31 RU RU2008150776/15A patent/RU2484815C2/ru active
- 2007-05-31 AU AU2007267135A patent/AU2007267135B2/en active Active
- 2007-05-31 EP EP07729688A patent/EP2063865A1/en not_active Withdrawn
- 2007-05-31 BR BRPI0711882-1A patent/BRPI0711882A2/pt not_active IP Right Cessation
-
2008
- 2008-11-30 IL IL195599A patent/IL195599A0/en unknown
- 2008-12-30 NO NO20085418A patent/NO20085418L/no not_active Application Discontinuation
-
2010
- 2010-04-21 HK HK10103896.7A patent/HK1137931A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008015339A (es) | 2008-12-16 |
| EP2063865A1 (en) | 2009-06-03 |
| JP2009543761A (ja) | 2009-12-10 |
| ZA200810834B (en) | 2010-03-31 |
| HK1137931A1 (en) | 2010-08-13 |
| BRPI0711882A2 (pt) | 2012-01-10 |
| CN101636145A (zh) | 2010-01-27 |
| WO2007138086A1 (en) | 2007-12-06 |
| NO20085418L (no) | 2009-02-26 |
| AU2007267135A1 (en) | 2007-12-06 |
| US20080051459A1 (en) | 2008-02-28 |
| RU2008150776A (ru) | 2010-07-10 |
| CA2653683A1 (en) | 2007-12-06 |
| AU2007267135B2 (en) | 2013-03-07 |
| KR20090057349A (ko) | 2009-06-05 |
| IL195599A0 (en) | 2009-09-01 |
| CN101636145B (zh) | 2014-04-23 |
| RU2484815C2 (ru) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA95954C2 (ru) | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа | |
| MX360289B (es) | Composiciones de tapentadol. | |
| ATE279175T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| GB2431346B (en) | A combination composition comprising paracetamol and ibuprofen | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| MX2009004616A (es) | Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente. | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| WO2005089872A3 (en) | Treatment of local pain | |
| UA105644C2 (ru) | Способы лечения легочных нарушений составами липосомального амикацина | |
| WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
| EA201000855A1 (ru) | Способ и средства для достижения бронхиальной релаксации | |
| MX352647B (es) | Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato. | |
| CA2632207C (en) | Use of calcitonin for the treatment of ra | |
| SE0400184D0 (sv) | New therapeutical use | |
| DE60218193D1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| EA200600626A1 (ru) | Композиция и лекарственная форма продолжительного выделения леводопы | |
| UA102111C2 (ru) | Фармацевтическая композиция в виде разовой пероральной дозы, которая содержит леводопу, карбидопу и энтакапон или их соли | |
| WO2009059242A8 (en) | A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use | |
| MX2008015323A (es) | Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion. | |
| DK1675611T3 (da) | Terapeutiske anvendelser for C-peptid | |
| MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
| WO2007144889A3 (en) | Treatment of neurofibromatosis |